Immunic Sign a License Agreement with University Medical Center Goettingen for IMU-838 & N4-Hydroxycytidine to Treat Viral Infections

September 23, 2021 Auto Bot Biotech, Immunic, viral infections 0

Shots:

  • The companies collaborated to evaluate IMU-838 (DHODH inhibitors) + NHC (nucleoside analogues) to treat patients with viral infections including COVID-19 and Influenza
  • The preclinical research showed that IMU-838 strongly synergizes with selected nucleoside analogues to inhibit SARS-CoV-2 replication in vitro. In vitro test system, IMU-838 & NHC alone showed 99.9% & 99% reduction in viral RNA at concentrations of 5μM & 100 nM
  • The enrollment of the first patient in the P-II CALLIPER trial of IMU-838 for MS is expected in Sept’21 & for the P-III ENSURE program in Q4’21. Additionally, the P-II results of IMU-838 in UC is expected to be available in Q2’22

Click here to­ read full press release/ article | Ref: Immunic | Image: PR Newswire

The post Immunic Sign a License Agreement with University Medical Center Goettingen for IMU-838 & N4-Hydroxycytidine to Treat Viral Infections first appeared on PharmaShots.